

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-25. (Canceled)

26. (Previously Presented): A substantially purified non-human antibody or fragment thereof which specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180.

27. (Previously Presented): A substantially purified non-human monoclonal antibody or fragment thereof which specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180.

28. (Previously Presented): The antibody of claim 27 which is a humanized antibody.

29. (Previously Presented): A monoclonal antibody or fragment thereof which specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180.

30-32 (Canceled)

33. (Previously Presented): A monoclonal antibody or fragment thereof which specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180, wherein the antibody is conjugated to a therapeutic moiety.

34. (Previously Presented): A monoclonal antibody or fragment thereof which specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180, wherein the antibody is conjugated to a detectable substance.

35. (Previously Presented): The antibody of claim 34, wherein the detectable substance is selected from the group consisting of an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material.

36. (Previously Presented): A substantially purified antibody or a fragment thereof which specifically binds to the extracellular domain of the amino acid sequence of SEQ ID NO:3, wherein said antibody or fragment thereof does not contain more than 30% of contaminating antibodies directed against epitopes other than those on the amino acid sequence of SEQ ID NO:3.

37. (Previously Presented): The antibody of claim 36, wherein the extracellular domain consists of amino acid residues 21 to 269 of SEQ ID NO:3.

38. (Previously Presented): The antibody of claim 36, wherein the extracellular domain consists of an immunoglobulin-like domain.

39. (Previously Presented): The antibody of claim 38, wherein the immunoglobulin-like domain consists of amino acid residues 48 to 88 or 134 to 180 of SEQ ID NO:3.

40. (Previously Presented): The antibody of claim 36 which is a polyclonal antibody.

41. (Previously Presented): A substantially purified antibody which specifically binds to the extracellular domain of the amino acid sequence of SEQ ID NO:3, wherein the antibody is a monoclonal antibody.

42. (Previously Presented): A substantially purified antibody which specifically binds to the extracellular domain of the amino acid sequence of SEQ ID NO:3, wherein the antibody is a chimeric antibody.

43. (Previously Presented): A substantially purified antibody which specifically binds to the extracellular domain of the amino acid sequence of SEQ ID NO:3, wherein the antibody is a humanized antibody.

44. (Previously Presented): The antibody of claim 36 which is a human antibody.

45. (Previously Presented): The antibody of claim 36, wherein the antibody is conjugated to a therapeutic moiety.

46. (Previously Presented): The antibody of claim 36, wherein the antibody is conjugated to a detectable substance.

47. (Previously Presented): The antibody of claim 46, wherein the detectable substance is selected from the group consisting of an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material.

48-52. (Canceled)

53. (Previously Presented): A kit comprising the antibody or fragment thereof as in claim 34, and instructions for use.

54. (Previously Presented): A kit comprising the antibody or fragment thereof as in claim 46, and instructions for use.

55-64. (Canceled)

65. (Previously Presented): A method of making an antibody that specifically binds to glycoprotein VI (GPVI), the method comprising:

a) immunizing a mammal with a polypeptide comprising the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180; and

b) collecting a sample from the mammal that contains an antibody that specifically binds to GPVI.

66. (Previously Presented): The method of claim 65 wherein the polypeptide is recombinantly produced.

67. (Previously Presented): The method of claim 65 which further comprises purifying antibodies from the sample.

68. (Previously Presented): The method of claim 65 which further comprises isolating a monoclonal antibody-producing cell from the mammal.

69. (Previously Presented): The method of claim 68 which further comprises collecting monoclonal antibodies which specifically bind to GPVI from the monoclonal antibody-producing cell.

70. (Previously Presented): The method of claim 65 wherein the antibody specifically binds to the extracellular domain of the amino acid sequence of SEQ ID NO:3.

71. (Previously Presented): A monoclonal antibody or fragment thereof which specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession

Number 207180, wherein the monoclonal antibody is a human antibody, a humanized antibody or a chimeric antibody.

72. (Previously Presented): The antibody of claim 71, wherein the antibody is conjugated to a therapeutic moiety.

73. (Previously Presented): The antibody of claim 71 wherein the antibody is conjugated to a detectable substance.

74. (Previously Presented): A monoclonal antibody or fragment thereof which is conjugated to a detectable substance selected from the group consisting of an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material, and which specifically binds to:

- a) a polypeptide comprising the amino acid sequence of SEQ ID NO:3; or
- b) the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number 207180,

wherein the monoclonal antibody is a human antibody, a humanized antibody or a chimeric antibody.

75. (Previously Presented): A kit comprising the antibody or fragment thereof as in claim 26, 87, 88, 89 or 90, and instructions for use.

76. (Previously Presented): A kit comprising the antibody or fragment thereof as in claim 27, and instructions for use.

77. (Previously Presented): A kit comprising the antibody or fragment thereof as in claim 29, and instructions for use.

78. (Previously Presented): A kit comprising a monoclonal antibody or fragment thereof which specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number 207180, wherein the monoclonal antibody is a human antibody, a humanized antibody or a chimeric antibody, and instructions for use.

79. (Previously Presented): A kit comprising a monoclonal antibody or fragment thereof which is conjugated to a detectable substance, and which specifically binds to:

- a) a polypeptide comprising the amino acid sequence of SEQ ID NO:3; or
 - b) the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number 207180,
- wherein the monoclonal antibody is a human antibody, a humanized antibody or a chimeric antibody, and instructions for use.

80-86. (Canceled)

87. (Previously Presented): The substantially purified non-human antibody of claim 26, wherein said antibody is at least 80% pure.

88. (Previously Presented): The substantially purified non-human antibody of claim 87, wherein said antibody is at least 90% pure.

89. (Previously Presented): The substantially purified non-human antibody of claim 88, wherein said antibody is at least 95% pure.

90. (Previously Presented): The substantially purified non-human antibody of claim 89, wherein said antibody is at least 99% pure.